{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:55:12Z","timestamp":1788263712555,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cannabidiol (CBD), a safe, non-intoxicating cannabis component, is growing in popularity in Europe and worldwide. However, CBD EU regulation is blurry, and consequent labelling and product quality issues may have implications for public health. There is therefore a need to assess the prevalence and perceived harmfulness of CBD use in EU countries, as well as to characterise CBD users. We aimed to do so in the French population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In December 2021, an online survey was conducted in a sample respecting the French adult population structure for key demographic variables. Sociodemographic, behavioural and CBD perception data were collected. Three separate regressions were performed to identify correlates of i) having heard of CBD, ii) using CBD, iii) perceived harmfulness of CBD. A hierarchical classification was also performed to identify profiles of CBD users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study sample comprised 1969 adults, of whom 69.2% had heard of CBD and 10.1% used it. Less than half (46.8%) of the former considered it harmful. Having heard of CBD was associated with younger age, being born in France, tobacco use, and cannabis use. CBD use was associated with younger age, tobacco use, cannabis use, poor self-reported general health status, and positive perception of alternative medicines. Cluster analysis revealed four different CBD user profiles based on socio-demographics and behavioural characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ten percent of the adults in this French study used CBD, and several user profiles emerged. Our results indirectly advocate clearer European CBD regulations to ensure safe and high-quality products.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-022-14057-0","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T03:06:09Z","timestamp":1661742369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cannabidiol use and perceptions in France: a national survey"],"prefix":"10.1186","volume":"22","author":[{"given":"Cl\u00e9mence","family":"Casanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Ramier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangui","family":"Barr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"issue":"3","key":"14057_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tips.2016.12.004","volume":"38","author":"EB Russo","year":"2017","unstructured":"Russo EB. Cannabidiol Claims and Misconceptions. Trends Pharmacol Sci. 2017;38(3):198\u2013201.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"14057_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","volume":"238","author":"SC Britch","year":"2021","unstructured":"Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology. 2021;238(1):9\u201328.","journal-title":"Psychopharmacology"},{"key":"14057_CR3","volume-title":"CANNABIDIOL (CBD), Critical Review Report","author":"Expert Committee on Drug Dependence","year":"2018","unstructured":"Expert Committee on Drug Dependence. CANNABIDIOL (CBD), Critical Review Report. Geneva: World Health Organization; 2018.\u00a0Available from:\u00a0https:\/\/www.who.int\/medicines\/access\/controlled-substances\/CannabidiolCriticalReview.pdf.\u00a0Cited 17 Jan 2022."},{"issue":"11","key":"14057_CR4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2020;45(11):1799\u2013806.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"14057_CR5","volume-title":"Low-THC cannabis products in Europe","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2020","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Low-THC cannabis products in Europe. Luxembourg: Publications Office of the European Union, L; 2020. Available from:\u00a0https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/13471\/TD0320749ENN01.pdf."},{"issue":"10","key":"14057_CR6","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1002\/ptr.7232","volume":"35","author":"SK Bhamra","year":"2021","unstructured":"Bhamra SK, Desai A, Imani-Berendjestanki P, Horgan M. The emerging role of cannabidiol (CBD) products; a survey exploring the public\u2019s use and perceptions of CBD. Phytother Res PTR. 2021;35(10):5734\u201340.","journal-title":"Phytother Res PTR"},{"key":"14057_CR7","unstructured":"French Council of State. L\u2019interdiction de vendre \u00e0 l\u2019\u00e9tat brut des fleurs et feuilles provenant de vari\u00e9t\u00e9s de cannabis sans propri\u00e9t\u00e9s stup\u00e9fiantes est suspendue. Conseil d\u2019\u00c9tat; 2022. Available from: https:\/\/www.conseil-etat.fr\/actualites\/l-interdiction-de-vendre-a-l-etat-brut-des-fleurs-et-feuilles-provenant-de-varietes-de-cannabis-sans-proprietes-stupefiantes-est-suspendue. Cited 3 Feb 2022."},{"issue":"3","key":"14057_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40429-020-00326-8","volume":"7","author":"DJ Sholler","year":"2020","unstructured":"Sholler DJ, Schoene L, Spindle TR. Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Curr Addict Rep. 2020;7(3):405\u201312.","journal-title":"Curr Addict Rep"},{"issue":"1","key":"14057_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42238-021-00078-w","volume":"3","author":"L Rapin","year":"2021","unstructured":"Rapin L, Gamaoun R, El Hage C, Arboleda MF, Prosk E. Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic. J Cannabis Res. 2021;3(1):19.","journal-title":"J Cannabis Res"},{"issue":"1","key":"14057_CR10","doi-asserted-by":"publisher","first-page":"bjgpopen20X1010","DOI":"10.3399\/bjgpopen20X101010","volume":"4","author":"G Gulbransen","year":"2020","unstructured":"Gulbransen G, Xu W, Arroll B. Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP Open. 2020;4(1):bjgpopen20X101010.","journal-title":"BJGP Open"},{"issue":"1","key":"14057_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/add.15587","volume":"117","author":"B Hughes","year":"2022","unstructured":"Hughes B, Vandam L, Mounteney J, Griffiths P. Regulatory approaches to cannabidiol in the European Union: are market developments sowing the seeds of confusion? Addiction. 2022;117(1):3\u20134.","journal-title":"Addiction"},{"key":"14057_CR12","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.12688\/f1000research.19931.1","volume":"8","author":"DW Lachenmeier","year":"2019","unstructured":"Lachenmeier DW, Habel S, Fischer B, Herbi F, Zerbe Y, Bock V, et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? F1000Research. 2019;8:1394.","journal-title":"F1000Research"},{"issue":"5","key":"14057_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/19390211.2020.1795044","volume":"17","author":"MJ Tallon","year":"2020","unstructured":"Tallon MJ. Cannabis sativa L. and its extracts: regulation of cannabidiol in the European Union and United Kingdom. J Diet Suppl. 2020;17(5):503\u201316.","journal-title":"J Diet Suppl"},{"issue":"6","key":"14057_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/dta.3220","volume":"14","author":"MC Monti","year":"2022","unstructured":"Monti MC, Zeugin J, Koch K, Milenkovic N, Scheurer E, Mercer-Chalmers-Bender K. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services. Drug Test Anal. 2022;14(6):1026\u2013103.","journal-title":"Drug Test Anal."},{"issue":"10","key":"14057_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","volume":"17","author":"MA Huestis","year":"2019","unstructured":"Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busard\u00f2 FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974\u201389.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"14057_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152\u201361.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"14057_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s42238-021-00102-z","volume":"3","author":"D Fortin","year":"2021","unstructured":"Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barr\u00e9 T. Reasons for using cannabidiol: a cross-sectional study of French cannabidiol users. J Cannabis Res. 2021;3(1):46.","journal-title":"J Cannabis Res"},{"issue":"1","key":"14057_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","volume":"3","author":"J Moltke","year":"2021","unstructured":"Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res. 2021;3(1):5.","journal-title":"J Cannabis Res"},{"key":"14057_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/0269881113477744","volume":"27","author":"CJ Morgan","year":"2013","unstructured":"Morgan CJ, Noronha LA, Muetzelfeldt M, Fielding A, Curran HV. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users. J Psychopharmacol Oxf Engl. 2013;27:497\u2013506.","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"9","key":"14057_CR20","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1111\/jgs.17213","volume":"69","author":"BH Han","year":"2021","unstructured":"Han BH, Funk-White M, Ko R, Al-Rousan T, Palamar JJ. Decreasing perceived risk associated with regular cannabis use among older adults in the United States from 2015 to 2019. J Am Geriatr Soc. 2021;69(9):2591\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"14057_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.drugalcdep.2017.12.041","volume":"186","author":"AL Sarvet","year":"2018","unstructured":"Sarvet AL, Wall MM, Keyes KM, Cerd\u00e1 M, Schulenberg JE, O\u2019Malley PM, et al. Recent rapid decrease in adolescents\u2019 perception that marijuana is harmful, but no concurrent increase in use. Drug Alcohol Depend. 2018;186:68\u201374.","journal-title":"Drug Alcohol Depend."},{"key":"14057_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.drugalcdep.2019.02.003","volume":"197","author":"Andreas J Burdzovic","year":"2019","unstructured":"Burdzovic Andreas J. Perceived harmfulness of various alcohol- and cannabis use modes: Secular trends, differences, and associations with actual substance use behaviors among Norwegian adolescents, 2007\u20132015. Drug Alcohol Depend. 2019;197:280\u20137.","journal-title":"Drug Alcohol Depend."},{"key":"14057_CR23","unstructured":"Goodman S, Wadsworth E, Schauer G, Hammond D. Use and Perceptions of Cannabidiol Products in Canada and in the United States. Cannabis Cannabinoid Res. 2020."},{"key":"14057_CR24","first-page":"1","volume":"10","author":"AFG Alayli","year":"2022","unstructured":"Alayli AFG, Kotz D, Kastaun S. Recreational Cannabidiol: Awareness, Prevalence of use, and Associated Factors in a Representative Sample of the German Population. Subst Use Misuse. 2022;10:1\u20138.","journal-title":"Subst Use Misuse"},{"key":"14057_CR25","unstructured":"MAGU-CBD. Survey on awareness and use of CBD [Befragung zur Bekanntheit & Nutzung von CBD] | www.emcdda.europa.eu. 2019 [cited 2022 Apr 4]. Available from: https:\/\/www.emcdda.europa.eu\/drugs-library\/survey-awareness-and-use-cbd-befragung-zur-bekanntheit-nutzung-von-cbd_en"},{"key":"14057_CR26","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3389\/fpsyt.2020.624012","volume":"11","author":"JR Vilches","year":"2021","unstructured":"Vilches JR, Taylor MB, Filbey FM. A Multiple Correspondence Analysis of Patterns of CBD Use in Hemp and Marijuana Users. Front Psychiatry. 2021;11:1583.","journal-title":"Front Psychiatry"},{"issue":"3","key":"14057_CR27","first-page":"433","volume":"28","author":"A Gagneux-Brunon","year":"2022","unstructured":"Gagneux-Brunon A, Botelho-Nevers E, Bonneton M, Peretti-Watel P, Verger P, Launay O, et al. Public opinion on a mandatory COVID-19 vaccination policy in France: a cross-sectional survey. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28(3):433\u20139.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"issue":"2","key":"14057_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00038-009-7104-y","volume":"54","author":"B Cox","year":"2009","unstructured":"Cox B, van Oyen H, Cambois E, Jagger C, le Roy S, Robine JM, et al. The reliability of the minimum European health module. Int J Public Health. 2009;54(2):55\u201360.","journal-title":"Int J Public Health"},{"key":"14057_CR29","first-page":"688","volume-title":"Pattern Classification, 2nd edition","author":"RO Duda","year":"2000","unstructured":"Duda RO, Hart PE, Stork DG. Pattern Classification, 2nd edition. 2nd ed. New York: Wiley; 2000. p. 688.\u00a0Available from:\u00a0https:\/\/www.wiley.com\/en-dk\/Pattern+Classification,+2nd+Edition-p-9780471056690.","edition":"2"},{"key":"14057_CR30","doi-asserted-by":"publisher","first-page":"107185","DOI":"10.1016\/j.addbeh.2021.107185","volume":"126","author":"MS Dunbar","year":"2022","unstructured":"Dunbar MS, Seelam R, Tucker JS, Firth CL, Pedersen ER, Klein DJ, et al. Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults. Addict Behav. 2022;126:107185.","journal-title":"Addict Behav"},{"key":"14057_CR31","doi-asserted-by":"publisher","unstructured":"Fortin D, Di Beo V, Massin S, Bisiou Y, Carrieri P, Barr\u00e9 T. A \u201cGood\u201d Smoke? The Off-Label Use of Cannabidiol to Reduce Cannabis Use. Front Psychiatry. 2022 [cited 2022 Mar 17];13. https:\/\/doi.org\/10.3389\/fpsyt.2022.829944","DOI":"10.3389\/fpsyt.2022.829944"},{"key":"14057_CR32","doi-asserted-by":"publisher","first-page":"626010","DOI":"10.3389\/fphar.2021.626010","volume":"12","author":"F Navarrete","year":"2021","unstructured":"Navarrete F, Garc\u00eda-Guti\u00e9rrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of cannabidiol in the therapeutic intervention for substance use disorders. Front Pharmacol. 2021;12:626010.","journal-title":"Front Pharmacol"},{"key":"14057_CR33","volume-title":"Cannabidiol (CBD): Analyse de situation","author":"F Zobel","year":"2019","unstructured":"Zobel F, Notari L, Schneider E, Rudmann O. Cannabidiol (CBD): Analyse de situation. Lausanne: Addiction Suisse; 2019. Available from:\u00a0https:\/\/idpc.net\/fr\/publications\/2019\/02\/cannabidiol-cbd-analyse-de-situation.\u00a0Cited 13 Feb\u00a02022. Report No.: 97."},{"issue":"7","key":"14057_CR34","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1080\/10826084.2020.1729201","volume":"55","author":"M Wheeler","year":"2020","unstructured":"Wheeler M, Merten JW, Gordon BT, Hamadi H. CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults. Subst Use Misuse. 2020;55(7):1138\u201345.","journal-title":"Subst Use Misuse"},{"issue":"13","key":"14057_CR35","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.3390\/ijerph18136719","volume":"18","author":"EC Leas","year":"2021","unstructured":"Leas EC, Moy N, McMenamin SB, Shi Y, Benmarhnia T, Stone MD, et al. Availability and Promotion of Cannabidiol (CBD) Products in Online Vape Shops. Int J Environ Res Public Health. 2021;18(13):6719.","journal-title":"Int J Environ Res Public Health"},{"key":"14057_CR36","first-page":"3083","volume":"2021","author":"M Soleymanpour","year":"2021","unstructured":"Soleymanpour M, Saderholm S, Kavuluru R. Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter. Proc IEEE Int Conf Bioinforma Biomed. 2021;2021:3083\u20138.","journal-title":"Proc IEEE Int Conf Bioinforma Biomed"},{"issue":"13","key":"14057_CR37","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/10826084.2020.1797808","volume":"55","author":"JW Merten","year":"2020","unstructured":"Merten JW, Gordon BT, King JL, Pappas C. Cannabidiol (CBD): Perspectives from Pinterest. Subst Use Misuse. 2020;55(13):2213\u201320.","journal-title":"Subst Use Misuse"},{"issue":"6","key":"14057_CR38","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/add.14174","volume":"113","author":"NC Salloum","year":"2018","unstructured":"Salloum NC, Krauss MJ, Agrawal A, Bierut LJ, Grucza RA. A reciprocal effects analysis of cannabis use and perceptions of risk. Addict Abingdon Engl. 2018;113(6):1077\u201385.","journal-title":"Addict Abingdon Engl"},{"issue":"4","key":"14057_CR39","first-page":"125","volume":"84","author":"C Galand","year":"2009","unstructured":"Galand C, Sal\u00e8s-Wuillemin \u00c9. La repr\u00e9sentation des drogues chez les \u00e9tudiants en psychologie\u202f: effets des pratiques de consommation et influence de l\u2019entourage. Cah Int Psychol Soc. 2009;84(4):125\u201352.","journal-title":"Cah Int Psychol Soc"},{"issue":"4","key":"14057_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/can.2019.0101","volume":"5","author":"J Corroon","year":"2020","unstructured":"Corroon J, MacKay D, Dolphin W. Labeling of Cannabidiol Products: A Public Health Perspective. Cannabis Cannabinoid Res. 2020;5(4):274\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"10","key":"14057_CR41","first-page":"942","volume":"111","author":"J Jooste","year":"2021","unstructured":"Jooste J, Laurens JB, Jordaan M, Marais AAS, Curlewis LG. The implications of the use of cannabidiol-related products in a safety-sensitive drug testing environment: A medical-legal perspective. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2021;111(10):942\u20135.","journal-title":"South Afr Med J Suid-Afr Tydskr Vir Geneeskd"},{"key":"14057_CR42","doi-asserted-by":"crossref","unstructured":"Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug\u2013Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019;8(7). Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6678684\/ Cited 26 Aug 2020.","DOI":"10.3390\/jcm8070989"},{"key":"14057_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","volume":"107","author":"AM Freeman","year":"2019","unstructured":"Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review Neurosci Biobehav Rev. 2019;107:696\u2013712.","journal-title":"A systematic review Neurosci Biobehav Rev"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-14057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T03:08:26Z","timestamp":1661742506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-14057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14057"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-14057-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"30 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was given by the Ethics Evaluation Committee of the French National Health and Medical Research Institute (CEEI Inserm, IRB 00003888, approval #21e770).Informed consent was obtained from all participants.All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1628"}}